- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02361541
Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, Cambodia (HCV-Epi)
Determination of Hepatitis C Prevalence, Genetic Diversity and Treatment Eligibility in an HIV Patient Cohort in Phnom Penh, Cambodia
Hepatitis C (HCV) is an important global public health problem, disproportionately affecting HIV positive populations. Asia and Africa account for most of the co-infection burden, but access to HCV screening and treatment is still very limited. It is expected though, with the recent therapeutic advances and increasing global advocacy efforts, that HCV treatment should become a feasible option in the near future.
Sihanouk Hospital Center of HOPE (Phnom Penh, Cambodia) is catering for one of the largest HIV cohorts of the country, followed in an ambulatory settings. In this cohort, the prevalence of HCV co-infection will be determined, as well as HCV genotype diversity and the severity of liver disease. The researcher will also explore the performance of simple blood tests/panels as predictors of significant fibrosis and/or cirrhosis.
Patients will attend two study-visits. All adult patients of the HIV patient cohort of SHCH will be proposed HCV testing during their next HIV follow-up consultation, following the latest algorithm of the Centre for Disease Control (CDC) (May 2013). Anamnesis and clinical examination will focus, additionally to routine practice, on presence of general and HCV liver-disease related features. Laboratory analyses will include basic HIV tests (CD4), and tests for liver function such as Hepatitis B surface antigen (HbsAg) .
During the following routine HIV follow-up consultation, the results of HCV testing will be explained to the patient. If the patient is HCV negative, his/her study participation ends here. If currently infected with HCV, the clinician will repeat the HCV liver-disease (extra-hepatic & hepatic) related anamnesis and clinical examination, and prescribe additional blood tests for the non-invasive liver fibrosis/cirrhosis blood panel tests, liver and kidney function. Patients will moreover be asked to undergo a liver ultrasound and liver stiffness measurements.
Aperçu de l'étude
Description détaillée
Hepatitis C (HCV) is an important global public health problem, disproportionally affecting HIV positive populations. Asia and Africa account for most of the co-infection burden, but access to HCV screening and treatment is still very limited. The high cost and complexity of current diagnostic and treatment algorithms are major bottlenecks and the linked lack of accurate HCV prevalence estimates and treatment-need data do not allow for robust treatment advocacy and program planning. Cambodia is not an exception.
It is expected though, with the recent therapeutic advances and increasing global advocacy efforts, that HCV treatment should become a feasible option in the near future. Sihanouk Hospital Center of HOPE (Phnom Penh, Cambodia) is catering for one of the largest HIV cohorts of the country, and it is planning to engage in HCV treatment from 2014 2015 onwards, with a double objective of direct patient benefit and catalyst role at national level, as in the past when starting its antiretroviral (ARV) program.
Within this specific setting, the researchers plan to determine the prevalence of HCV co-infection, HCV genotype diversity and severity of liver disease in this HIV patient cohort, followed in an ambulatory setting. The researchers will also explore the performance of simple blood tests/panels as predictors of significant fibrosis and/or cirrhosis .
The current HCV diagnostic procedures (and tools), as applied in this study, are too expensive and resource-demanding to allow for scalability in resource limited settings. Thus, the researchers plan to set up during this study a biobank with samples of a clinically well described HIV patient population. These samples should allow constituting a well-balanced panel for evaluation of future 'more scalable' HCV diagnostic tools.
Patients will attend two study-visits. All adult patients of the HIV cohort will be proposed HCV testing during their next regular HIV follow-up consultation. HCV testing will follow the latest algorithm of the Centre for Disease Control (CDC) (May 2013). During this same consultation, anamnesis and clinical examination will focus, additionally to routine practice ,on presence of general and HCV liver-disease related features. Laboratory analyses will also include basic HIV (CD4), and tests for liver function such as Hepatitis B surface antigen (HbsAg).
During the following routine HIV follow-up consultation (2-3 months later), the results of HCV testing will be explained to the patient. If the patient is HCV negative, his/her study participation ends here. If currently infected with Hepatitis C, the clinician will repeat the HCV liver-disease (extra-hepatic & hepatic) related anamnesis and clinical examination and prescribe additional blood tests for the non-invasive liver fibrosis/cirrhosis blood panel tests, liver and kidney function. Patients will moreover be asked to undergo a liver ultrasound and liver stiffness measurements.
The biobank will be set up with left over biological samples (whole blood plasma and serum) and comprehensive clinical information of all patients who give additional consent for this scope. Both biological samples and clinical information will be coded, to ensure confidentiality.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Phnom Penh, Cambodge
- Sihanouk Hospital Center of HOPE (SHCH), Cambodia
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Adult (> or = 18 years old)
- Documented HIV positive
- In regular HIV care follow-up (min. 2 consultations in the last six months prior to the study)
- Willing and able to provide written informed consent
Exclusion Criteria:
• HIV patients with currently taking Hepatitis C treatment or with a history of prior hepatitis C treatment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
HCV screening
All adult patients of an existing HIV cohort
|
HCV antibody screening, liver function tests, full blood count and HbsAg will performed.
Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping).
For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Seroprevalence of HCV infection
Délai: Baseline
|
Seroprevalence of HCV infection in the HIV patient cohort
|
Baseline
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Proportion of current HCV infection
Délai: Baseline
|
Proportion of currently infected with HCV among the HCV-IgG positive HIV patients
|
Baseline
|
Proportion of HCV false-positives
Délai: Baseline
|
Proportion of HCV biologically false-positives among HCV-IgG positive screening
|
Baseline
|
HCV genotypes
Délai: Baseline
|
Proportions of different HCV genotypes
|
Baseline
|
Severity of liver disease in HCV patients
Délai: Baseline
|
To determine the severity of liver disease by transient elastography in this coinfected cohort
|
Baseline
|
HCV diagnostic accuracy
Délai: Baseline
|
To compare the diagnostic accuracy of commonly available blood panel tests for fibrosis staging in this coinfected cohort, with liver stiffness measurement (considered as reference standard).
|
Baseline
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Anja De Weggheleire, MD, Institute of Tropical Medicine, Antwerp, Belgium
- Chercheur principal: An Sokkab, MD, Sihanouk Hospital Center of HOPE (SHCH), Cambodia
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- HCV-Epi
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur HCV screening
-
TransgeneComplété
-
Foundation for Innovative New Diagnostics, SwitzerlandUNITAIDComplétéHépatite C chroniqueAustralie, Cameroun, Géorgie, Grèce, Rwanda
-
Kirby InstituteRecrutement
-
Centre Hospitalier Universitaire Saint PierreAbbVie; Gilead Sciences; Cepheid; Réseau Hépatite C BruxellesComplétéHépatite C chroniqueBelgique
-
Johns Hopkins UniversityPas encore de recrutement
-
Foundation for Innovative New Diagnostics, SwitzerlandComplété
-
Macfarlane Burnet Institute for Medical Research...Gilead SciencesComplété
-
MedMira Laboratories Inc.RetiréInfections à VIH | Infections à l'hépatite B | Infections à l'hépatite CÉtats-Unis
-
Asociación Colombiana de HepatologíaHospital Pablo Tobón UribeRecrutementInfection par le virus de l'hépatite CColombie
-
TruCare Internal Medicine & Infectious DiseaseGilead SciencesComplété